Analyst consensus rating
FibroBiologics Analyst Rating: none
FBLG is rated none by 2 analysts with a $12.50 target. As of 2026-08-27.
Direct answer
FibroBiologics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.50.
Forecast evidence checked August 27, 2026.
Get free FibroBiologics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.41
- Average price target
- $12.50
- High price target
- $19.00
- Low price target
- $6.00
- Low target gap
- +325.5%
- Target upside
- +786.5%
- High target gap
- +1,247.5%
- Target range width
- 922%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for FibroBiologics?
FibroBiologics has a verified none consensus. The same dataset has an average price target of $12.50.
How far are FibroBiologics's low and high targets from the recorded price?
The low target implies +325.5%, while the high target implies +1,247.5%.
How many analysts are included in FibroBiologics's consensus?
The verified consensus includes 2 analysts.
How is FibroBiologics's target upside or downside calculated?
The average target of $12.50 is divided by the recorded price of $1.41, then one is subtracted to produce +786.5%. This does not guarantee a future return.
When was FibroBiologics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.